181 related articles for article (PubMed ID: 24825754)
21. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
Marino P; Bertucci F; Gonçalves A; Seror V
Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
[TBL] [Abstract][Full Text] [Related]
22. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
24. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
[No Abstract] [Full Text] [Related]
25. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
26. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
27. Does evidence-based medicine really reduce costs?
Kolodziej MA
Oncology (Williston Park); 2011 Mar; 25(3):214, 218. PubMed ID: 21548463
[TBL] [Abstract][Full Text] [Related]
28. The translational potential of circulating tumour DNA in oncology.
Patel KM; Tsui DW
Clin Biochem; 2015 Oct; 48(15):957-61. PubMed ID: 25889059
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers in veterinary cancer screening: Applications, limitations and expectations.
Henry CJ
Vet J; 2010 Jul; 185(1):10-4. PubMed ID: 20510636
[TBL] [Abstract][Full Text] [Related]
30. The economic evaluation of personalised oncology medicines: ethical challenges.
Lewis JR; Lipworth WL; Kerridge IH; Day RO
Med J Aust; 2013 Oct; 199(7):471-3. PubMed ID: 24099207
[TBL] [Abstract][Full Text] [Related]
31. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
32. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
34. How much is the life of a cancer patient worth? A pharmaco-economic perspective.
Simoens S; Dooms M
J Clin Pharm Ther; 2011 Jun; 36(3):249-56. PubMed ID: 21545607
[TBL] [Abstract][Full Text] [Related]
35. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
36. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?
Uyl-de Groot CA; Giaccone G
Curr Opin Oncol; 2005 Jul; 17(4):392-6. PubMed ID: 15933476
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments.
Vithanachchi DT; Maujean A; Downes MJ; Scuffham P
Br J Clin Pharmacol; 2021 Feb; 87(2):271-283. PubMed ID: 32692416
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
39. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
